证券代码：688677 证券简称：海泰新光 公告编号：2024-066 青岛海泰新光科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/5/9 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 万元~5,000 万元 2,600 | | 回购价格上限 | 69 元/股 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 万股 73.7 | | 实际回购股数占总股本比例 | 0.6110% | | 实际回购金额 | 万元 2,610.96 | | 实际回购价格区间 | 28.89 元/股~40.75 元/股 | 一、 回购审批情况和回购方案内容 2024 年 5 月 8 日，公司召开第三届董事会第二十次会议，审议通过了《关于 以集中竞价交易方式回 ...

Investment Rating - The report maintains a positive outlook on the company, indicating a potential recovery in revenue growth as the inventory reduction by major US customers nears its end [1] Core Views - The company's revenue for the first three quarters of 2024 was RMB 319 million (yoy -15 30%), with net profit attributable to the parent company at RMB 97 40 million (yoy -17 60%) [1] - Revenue in Q3 2024 was RMB 98 25 million (yoy -9 39%), showing a narrowing decline compared to previous quarters, suggesting the inventory reduction cycle is nearing its end [1] - The company's gross profit margin in Q3 2024 improved to 69 44% (yoy +5pp), driven by higher-margin products [1] - The company's second growth driver, the whole machine business, continued to grow significantly in Q3 2024, providing new momentum for future growth [1] Financial Performance Summary - Revenue for 2024E is projected at RMB 436 million (yoy -7 4%), with a recovery expected in 2025E and 2026E to RMB 555 million (yoy +27 3%) and RMB 684 million (yoy +23 3%) respectively [2] - Net profit attributable to the parent company is forecasted to grow from RMB 155 million in 2024E to RMB 254 million in 2026E, with a CAGR of 25 7% [2] - Gross profit margin is expected to remain stable at around 63 9% from 2024E to 2026E [2] - ROE is projected to improve from 11 7% in 2024E to 15 8% in 2026E, reflecting better profitability and efficiency [2] Business Outlook - The company's revenue growth is expected to recover as the inventory reduction by major US customers concludes, with shipments expected to gradually increase [1] - The whole machine business is anticipated to become a significant growth driver, contributing to the company's future revenue expansion [1] - The company's profitability is expected to remain stable, with potential for improvement as revenue scales up and expenses are diluted [1] Valuation Metrics - The company's P/E ratio is projected to decline from 29 84x in 2024E to 18 23x in 2026E, reflecting expected earnings growth [2] - The P/B ratio is forecasted to decrease from 3 48x in 2024E to 2 88x in 2026E, indicating potential undervaluation as the company's book value grows [2]

青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议资料 2024 年 11 月 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议资料 目录 | 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议须知 1 | | --- | | 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议议程 3 | | 议案一、《关于投保董事、监事及高级管理人员等人员责任保险的议案》 ... 4 | | 议案二：《关于修订<青岛海泰新光科技股份有限公司对外投资管理制度>的议 | | 案》 5 | 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议资料 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议资料 证券代码：688677 证券简称：海泰新光 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议须知 为了维护青岛海泰新光科技股份有限公司全体股东的合法权益，确保股东大 会的正常秩序和议事效率，保证大会的顺利进行，根据《中华人民共和国公司 法》、《中华人民共和国证券法》、中国证监会《上市公司股东大会规则》以及 《公司章程》、《青岛海泰新 ...

7、整机有受到医疗反腐的影响吗？ A：国内医疗市场受反腐影响很大，今年上半年尤其明显，招标数 量很少，从下半年开始有所恢复。 8、以旧换新的推进情况？ | 来访者类型 | 特定对象调研 分析师会议 策略会 | | | --- | --- | --- | | | 媒体采访  业绩说明会 | 新闻发布会 | | | 路演活动 公司来访 电话会议 |  其他 | | 来 访 人 员 姓 | 详见附件 | | | 名、身份证 | | | | 号及职务 | | | | 接待时间 | 10 月 28 日 预约接待地点 / | | | | 【130】人 接待人员 董事、总经理郑耀，独立 董事王鸣，副总经理、董 | | | 参会投资者 | | | | | 事会秘书、财务总监汪方 | | | | 华 | | | | 1、三季度内窥镜的发货情况？四季度和明年的情况会怎样？ | | | | A：公司今年第三季度内窥镜发货数量是近几年来最少的一个季度， | | | | 主要是受大客户消库存的影响。目前大客户的库存已经降到了一个 | | | | 很低的水平，从第四季度和明年年初的发货需求来看，数量相比第 | | | | 三 ...

Investment Rating - Buy rating maintained for Haitui New Light (688677) [1] Core Views - Performance pressure in 2024Q3, with a potential turning point expected in 2024Q4 [1] - Revenue for the first three quarters of 2024 was RMB 319 million, down 15.30% YoY, with net profit attributable to the parent company at RMB 97 million, down 17.60% YoY [1] - In 2024Q3, revenue was RMB 98 million, down 9.39% YoY, with net profit attributable to the parent company at RMB 27 million, down 7.00% YoY [1] - The decline in revenue is attributed to inventory reduction by a major US customer, but the rate of decline has narrowed compared to previous quarters [1] - Strong collaboration with the major US customer, with joint development of next-generation endoscope systems and plans to add anti-fogging features [1] - Overseas capacity expansion is progressing smoothly, with the US subsidiary in Nevada starting to receive orders and the Thai factory expected to achieve mass production by 2025 [1] Financial Projections - Revenue for 2024-2026 is projected to be RMB 437 million, RMB 542 million, and RMB 650 million, with growth rates of -7.1%, 24.1%, and 19.9% respectively [1] - Net profit attributable to the parent company for 2024-2026 is expected to be RMB 133 million, RMB 187 million, and RMB 226 million, with growth rates of -9.0%, 41.4%, and 20.5% respectively [1] - PE ratios for 2024-2026 are projected at 35x, 25x, and 20x [1] Financial Performance - Gross margin for 2023 was 63.7%, expected to increase to 65.3% in 2024, 66.0% in 2025, and 66.5% in 2026 [3] - ROE for 2023 was 11.3%, expected to be 9.3% in 2024, 11.6% in 2025, and 12.3% in 2026 [3] - EPS for 2024-2026 is projected to be RMB 1.10, RMB 1.55, and RMB 1.87 [3] Operational Highlights - The company's US subsidiary in Nevada passed customer certification in July 2024 and began receiving orders for endoscopes [1] - The 4mm hysteroscope developed for the US customer has entered mass production, with shipments starting in June 2024 [1] - The Thai factory obtained BUI and production licenses in 2024Q3, with plans to apply for customer approval in November and December 2024, aiming for mass production in 2025Q1 [1]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's performance is under short-term pressure due to downstream inventory destocking, but the destocking process is nearing its end [2] - The company's Q3 revenue remains under pressure, with a single-quarter revenue of 98 million yuan (-9.39% YoY) and net profit of 27 million yuan (-7.00% YoY) [2] - The company is actively expanding overseas, with its Thailand subsidiary expected to achieve mass production next year, enhancing its competitiveness [2] - The company's main business is expected to recover steadily next year, supported by stable cooperation with a major US customer and the domestic equipment replacement policy [3] - The report adjusts the company's net profit forecasts for 2024-2026 to 140/204/250 million yuan, with corresponding PE valuations of 31/21/17 times [3] Financial Performance - The company's revenue for the first three quarters of 2024 was 319 million yuan (-15.30% YoY), with net profit of 97 million yuan (-17.60% YoY) [2] - The company's revenue for 2024 is expected to be 395.41 million yuan (-15.98% YoY), with net profit of 139.62 million yuan (-4.18% YoY) [1] - The company's revenue for 2025 is expected to be 523.29 million yuan (+32.34% YoY), with net profit of 203.63 million yuan (+45.85% YoY) [1] - The company's revenue for 2026 is expected to be 631.96 million yuan (+20.77% YoY), with net profit of 250.13 million yuan (+22.83% YoY) [1] Business Segments - The company's medical endoscope products and light source modules saw a decline in revenue due to downstream inventory destocking, while endoscope maintenance and complete equipment sales showed significant growth [2] - The company sold approximately 150 sets of complete equipment in the first three quarters of 2024, with full-year sales expected to grow steadily [2] Overseas Expansion - The company's Thailand factory has obtained BUI and production licenses, with production lines for new endoscope products and light source modules established [2] - The company plans to apply for customer approval in November and December, aiming for mass production in the first quarter of next year [2] Valuation and Metrics - The company's current PE ratio is 31.19 times, with expected PE ratios of 21.38 and 17.41 times for 2025 and 2026, respectively [1] - The company's current PB ratio is 3.40 times, with expected PB ratios of 3.14, 2.74, and 2.37 times for 2024, 2025, and 2026, respectively [10] - The company's ROE for 2024 is expected to be 10.08%, increasing to 12.82% and 13.61% in 2025 and 2026, respectively [10] Market Data - The company's closing price is 36.10 yuan, with a one-year low/high of 25.48/61.99 yuan [5] - The company's market capitalization is 4,354.17 million yuan, with a circulating A-share market capitalization of 4,354.17 million yuan [5] Financial Statements - The company's total assets are expected to increase from 1,395 million yuan in 2023 to 1,962 million yuan in 2026 [9] - The company's net cash flow from operating activities is expected to increase from 158 million yuan in 2023 to 331 million yuan in 2026 [10] - The company's capital expenditures are expected to be 92 million yuan in 2024, 92 million yuan in 2025, and 94 million yuan in 2026 [10]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing a continuous inventory digestion from major clients, leading to an acceleration in the maturity of its complete machine business. Despite a decline in revenue and net profit in the first three quarters of 2024, the company is expected to see a gradual recovery in shipment volumes as client inventory levels decrease. The international business localization capabilities are improving significantly, which is anticipated to enhance the competitiveness of domestic operations [1][3]. Financial Performance Summary - **Revenue (in million CNY)**: - 2022: 477 - 2023: 471 - 2024E: 414 - 2025E: 517 - 2026E: 653 - **Year-over-Year Growth Rate**: - 2022: 54% - 2023: -1% - 2024E: -12% - 2025E: 25% - 2026E: 26% [1] - **Net Profit (in million CNY)**: - 2022: 183 - 2023: 146 - 2024E: 146 - 2025E: 178 - 2026E: 221 - **Year-over-Year Growth Rate**: - 2022: 55% - 2023: -20% - 2024E: 1% - 2025E: 21% - 2026E: 24% [1] - **Earnings Per Share (in CNY)**: - 2022: 2.10 - 2023: 1.20 - 2024E: 1.20 - 2025E: 1.46 - 2026E: 1.82 [1] Business Outlook - The company has reported a revenue of 3.19 billion CNY for the first three quarters of 2024, a year-over-year decline of 15.30%. The net profit for the same period is 0.97 billion CNY, down 17.60% year-over-year. The decline is attributed to the impact of major clients reducing inventory levels [1][3]. - The company is expected to see a recovery in shipment volumes as client inventory levels decrease, with a focus on expanding its international business and enhancing local delivery capabilities [1][3]. Cost and Profitability Analysis - The company has increased its marketing and R&D investments, leading to a relatively stable profitability profile. The sales expense ratio for the first three quarters of 2024 is reported at 4.91%, with management and financial expense ratios also showing slight increases [1][3]. - The gross profit margin for the first three quarters of 2024 is 65.74%, reflecting a year-over-year increase, while the net profit margin is reported at 30.78%, showing a slight decline [1][3].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook on its order recovery and profitability forecasts [4]. Core Views - The company's Q3 performance met market expectations, with a revenue of 319 million yuan for the first three quarters, a 15% year-on-year decline, and a net profit of 97 million yuan, down 18% year-on-year [4]. - The gross margin improved significantly, reaching 65.74% for the first three quarters, compared to 64.10% in the same period last year, driven by an increase in high-margin products [4]. - The report expresses optimism about the recovery of orders, anticipating a significant improvement in performance starting from Q4 due to inventory clearance and new product contributions [4]. Financial Data and Profit Forecast - Total revenue for 2023 is projected at 471 million yuan, with a slight decline expected in Q1-Q3 2024 to 319 million yuan, followed by a recovery to 521 million yuan in 2024 [5]. - The net profit for 2023 is estimated at 146 million yuan, with a forecasted increase to 166 million yuan in 2024, representing a 13.7% year-on-year growth [5]. - The report projects earnings per share to rise from 1.20 yuan in 2023 to 1.37 yuan in 2024, reflecting a positive trend in profitability [5].

证券代码：688677 证券简称：海泰新光 公告编号：2024-063 青岛海泰新光科技股份有限公司 第四届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 青岛海泰新光科技股份有限公司（以下简称"公司"）第四届董事会第二次 会议于 2024 年 10 月 24 日 9:00 在公司会议室以现场与通讯表决相结合的方式召 开，会议通知于 2024 年 10 月 11 日以邮件方式送达。公司董事 7 人，实际参会 董事 7 人。会议由公司董事长郑安民先生主持，会议的召集和召开程序符合《中 华人民共和国公司法》和《公司章程》等相关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 经与会董事投票表决，审议通过了如下议案： （一）审议通过《青岛海泰新光科技股份有限公司 2024 年第三季度报告》; 详情见《青岛海泰新光科技股份有限公司 2024 年第三季度报告》。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 （三）审议通过《关于修订<青岛海泰新光科技股份有限公司对外投 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥98,254,526.72, a decrease of 9.39% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was ¥26,842,224.85, down 7.00% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥24,504,318.59, a decrease of 2.79% compared to the same period last year[2] - Total operating revenue for the first three quarters of 2024 was CNY 318,670,736.92, a decrease of 15.3% compared to CNY 376,245,393.03 in the same period of 2023[12] - Net profit for the first three quarters of 2024 was CNY 96,418,838.54, down 16.7% from CNY 115,793,532.85 in 2023[13] - The basic earnings per share for Q3 2024 was ¥0.22, a decrease of 8.33% compared to the same period last year[3] - The company reported a basic earnings per share of CNY 0.81, down from CNY 0.97 in the previous year[13] Research and Development - The total R&D investment for Q3 2024 was ¥16,338,612.14, a decline of 17.22% year-on-year[3] - The R&D investment accounted for 16.63% of operating revenue, a decrease of 1.57 percentage points compared to the same period last year[3] - Research and development expenses were CNY 47,153,360.06, a decrease of 13.0% from CNY 54,209,502.81 in the previous year[12] - The company is investing 50 million RMB in R&D for new technologies aimed at enhancing product efficiency[16] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥91,776,890.23, down 16.07% year-on-year[2] - The company's cash and cash equivalents decreased to ¥434.73 million from ¥592.32 million, representing a decline of approximately 26.6%[10] - The total assets at the end of the reporting period were ¥1,395,826,579.98, a slight increase of 0.07% from the end of the previous year[3] - As of September 30, 2024, the company's total current assets amounted to approximately ¥830.77 million, a decrease from ¥904.92 million as of December 31, 2023, reflecting a decline of about 8.2%[10] - The company's total assets remained relatively stable, totaling ¥1.40 billion as of September 30, 2024, compared to ¥1.39 billion at the end of 2023[11] Liabilities and Equity - The total liabilities of the company increased to ¥114.99 million from ¥102.10 million, marking an increase of about 12.5%[11] - The company maintains a strong equity position with total equity amounting to approximately ¥1.28 billion, slightly down from ¥1.29 billion[11] Market and Strategic Developments - The company experienced a significant impact on revenue due to the continued inventory reduction by major customers in the U.S.[6] - The company has not disclosed any new product developments or market expansion strategies in the current report[10] - Market expansion efforts have led to a 30% increase in market share in the Asia-Pacific region[16] - The company is exploring potential acquisitions to enhance its technology portfolio, with a budget of 200 million RMB allocated for this purpose[16] - A new strategic partnership was announced, expected to generate an additional 100 million RMB in revenue over the next year[16] Future Outlook - The company provided a forward guidance of 10% revenue growth for Q4 2024, projecting revenues to reach approximately 1.32 billion RMB[16] - The company plans to increase its marketing budget by 15% to support brand awareness and customer acquisition initiatives[16] Operational Efficiency - The gross margin improved to 40%, up from 35% in the previous quarter, reflecting better cost management[16] - The company reported a revenue increase of 15% year-over-year, reaching 1.2 billion RMB in Q3 2024[16] - User data showed a growth of 20% in active users, totaling 5 million by the end of Q3 2024[16] - New product launches contributed to a 25% increase in sales, with the latest product line accounting for 300 million RMB in revenue[16]